TACROLIMUS EXTENDED RELEASE CAPSULES and COVID 19

Overview

COVID 19 is the #10 most commonly reported adverse reaction for TACROLIMUS EXTENDED RELEASE CAPSULES, manufactured by Astellas Pharma US, Inc.. There are 3,632 FDA adverse event reports linking TACROLIMUS EXTENDED RELEASE CAPSULES to COVID 19. This represents approximately 2.0% of all 181,869 adverse event reports for this drug.

TACROLIMUS EXTENDED RELEASE CAPSULES has an overall safety score of 92 out of 100. Patients taking TACROLIMUS EXTENDED RELEASE CAPSULES who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COVID 19 is a less commonly reported adverse event for TACROLIMUS EXTENDED RELEASE CAPSULES, but still significant enough to appear in the safety profile.

Other Side Effects of TACROLIMUS EXTENDED RELEASE CAPSULES

In addition to covid 19, the following adverse reactions have been reported for TACROLIMUS EXTENDED RELEASE CAPSULES:

• OFF LABEL USE — 11,734 reports
• DRUG INEFFECTIVE — 8,329 reports
• PRODUCT USE IN UNAPPROVED INDICATION — 5,813 reports
• DRUG INTERACTION — 5,363 reports
• ACUTE KIDNEY INJURY — 5,057 reports
• DIARRHOEA — 4,324 reports
• TRANSPLANT REJECTION — 3,983 reports
• CYTOMEGALOVIRUS INFECTION — 3,844 reports
• PYREXIA — 3,690 reports
• TOXICITY TO VARIOUS AGENTS — 3,493 reports

Other Drugs Associated with COVID 19

The following drugs have also been linked to covid 19 in FDA adverse event reports:

Does TACROLIMUS EXTENDED RELEASE CAPSULES cause COVID 19?

COVID 19 has been reported as an adverse event in 3,632 FDA reports for TACROLIMUS EXTENDED RELEASE CAPSULES. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COVID 19 with TACROLIMUS EXTENDED RELEASE CAPSULES?

COVID 19 accounts for approximately 2.0% of all adverse event reports for TACROLIMUS EXTENDED RELEASE CAPSULES, making it a notable side effect.

What should I do if I experience COVID 19 while taking TACROLIMUS EXTENDED RELEASE CAPSULES?

If you experience covid 19 while taking TACROLIMUS EXTENDED RELEASE CAPSULES, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages